We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

83 hedge funds and large institutions have $208M invested in Adverum Biotechnologies in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,750% more call options, than puts

Call options by funds: $194K | Put options by funds: $4K

72% more capital invested

Capital invested by funds: $121M → $208M (+$87M)

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

0.17% more ownership

Funds ownership: 6.11% → 6.28% (+0.17%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less funds holding

Funds holding: 86 → 83 (-3)

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

Holders
83
Holders Change
-3
Holders Change %
-3.49%
% of All Funds
1.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
26
Reduced
22
Closed
14
Calls
$194K
Puts
$4K
Net Calls
+$190K
Net Calls Change
+$113K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$5.03M
2
UBS Group
UBS Group
Switzerland
+$4.82M
3
ACP
Acuta Capital Partners
California
+$3.72M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.9M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.5M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$6.04M
2
Man Group
Man Group
United Kingdom
-$2.04M
3
WM
WS Management
Florida
-$1.6M
4
PA
Perceptive Advisors
New York
-$960K
5
Two Sigma Investments
Two Sigma Investments
New York
-$801K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$32.8M – – –
BlackRock
2
BlackRock
New York
$22.6M -$502K -12,430 -3%
Renaissance Technologies
3
Renaissance Technologies
New York
$19.9M +$309K +7,653 +2%
JP Morgan Chase
4
JP Morgan Chase
New York
$17.3M +$1.5M +37,146 +13%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$15.7M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$11.1M +$1.9M +47,044 +29%
UBS Group
7
UBS Group
Switzerland
$10.8M +$4.82M +119,311 +137%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$9.97M +$541K +13,390 +8%
O
9
OrbiMed
New York
$6.51M +$5.03M +124,320 New
EAM
10
Eventide Asset Management
Massachusetts
$6.01M – – –
Primecap Management
11
Primecap Management
California
$5.51M – – –
State Street
12
State Street
Massachusetts
$4.97M +$140K +3,451 +4%
ACP
13
Acuta Capital Partners
California
$4.82M +$3.72M +91,900 New
WM
14
WS Management
Florida
$4.66M -$1.6M -39,668 -31%
B
15
Bpifrance
France
$4.34M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$4.15M +$380K +9,402 +13%
Northern Trust
17
Northern Trust
Illinois
$3.17M +$162 +4 +0%
SFSIG
18
San Francisco Sentry Investment Group
California
$2.52M – – –
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$2.1M +$1M +24,806 +163%
6CM
20
683 Capital Management
New York
$1.9M – – –
Ameriprise
21
Ameriprise
Minnesota
$1.42M +$448K +11,071 +69%
BCM
22
Bridgeway Capital Management
Texas
$1.17M +$139K +3,440 +18%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.14M -$323 -8 -0%
Victory Capital Management
24
Victory Capital Management
Texas
$1.08M -$9.42K -233 -1%
Axa
25
Axa
France
$918K +$25.1K +620 +4%
1
2 3 4

ADVM Hedge Fund Activity: Q1 2019 in Review

83 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2019, worth a combined $208M — up 72% from $121M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of ADVM and 11 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 26 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $5.03M. The largest seller was Citadel Advisors, cutting an estimated $6.04M.

  • 83 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2019, down from 86 in Q4 2018.
  • Funds reported $208M of Adverum Biotechnologies stock for Q1 2019, up 72% quarter-over-quarter.
  • 11 funds opened new Adverum Biotechnologies positions in Q1 2019 and 14 closed out, a net change of -3 holders.
  • The largest Adverum Biotechnologies buyer in Q1 2019 was OrbiMed, an estimated $5.03M added.
  • The largest Adverum Biotechnologies seller in Q1 2019 was Citadel Advisors, an estimated $6.04M sold.

Based on aggregated 13F filings for Q1 2019.